Monitoring and Managing Hyperphosphatemia

EP: 1.Intrahepatic Cholangiocarcinoma Overview

EP: 2.Risk Factors Leading to Various Liver Cancers

EP: 3.Clinical Presentations of Patients With Cholangiocarcinoma

EP: 4.The Role of Biomarker Testing in Diagnosing Cholangiocarcinoma

EP: 5.First- and Second-Line Treatment Options for Intrahepatic Cholangiocarcinoma With FGFR2 Fusions or Alterations

EP: 6.Next-Gen Inhibitors Shaping Cholangiocarcinoma Treatment Landscape

EP: 7.Key Highlights For Patient Education Surrounding FGFR Inhibitors

EP: 8.Common Adverse Events Associated With FGFRi Therapy

EP: 9.Patient Perspective Regarding FGFRi Adverse Event Profiles

EP: 10.Symptoms Associated With Eye-Related Toxicities Amid FGFRi Therapy

Now Viewing

EP: 11.Monitoring and Managing Hyperphosphatemia

EP: 12.Navigating FGFRi Therapy Adverse Effects: Nail Toxicities

EP: 13.FGFRi-Related Stomatitis and Dry Mouth Impacting Patient Quality of Life

EP: 14.Key Takeaways For Treating Patients Diagnosed With Cholangiocarcinoma

This page is funded by Taiho Oncology, Inc. The faculty and publisher are solely responsible for this content. Taiho does not recommend or endorse the use of its products other than as described in the approved labeling. The content of this page is not medical advice and does not replace independent medical judgment.

This is a video synopsis/summary of an OncLive Insights involving Lipika Goyal, MD; Chaundra Bishop; R. Katie Kelley, MD; and Caroline Kuhlman, NP.

Hyperphosphatemia, defined in clinical trials as a serum phosphorus level greater than 5.5 mg/dL, is a common adverse effect of patients taking FGFR inhibitors such as pemigatinib and futibatinib. Monitoring serum phosphorus levels at 1 to 2 weeks after starting an FGFR inhibitor is recommended. Although patients can attempt a low-phosphorus diet, this is often insufficient to control hyperphosphatemia on its own. Instead, phosphate binders such as sevelamer hydrochloride are typically needed. Adherence to phosphate binders can be challenging due to high pill burden, need to take with meals, and potential adverse effects such as constipation or diarrhea. Rarely is the FGFR inhibitor dose reduced or held solely due to hyperphosphatemia. Even phosphorus levels above 7 mg/dL can often be managed with aggressive treatment using maximum doses of sevelamer and acetazolamide without needing to alter the FGFR inhibitor regimen. However, long-term treatment with high-dose sevelamer may not be well tolerated due to adverse effects.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.